Overview

Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC

Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The central hypothesis is to test Low Dose Fraction Radiotherapy (LDFRT), as a potentiator of Docetaxel and Cisplatin efficacy in locally advanced nasopharyngeal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Treatments:
Cisplatin
Docetaxel